<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mesalamine (mesalazine): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mesalamine (mesalazine): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mesalamine (mesalazine): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10842" href="/d/html/10842.html" rel="external">see "Mesalamine (mesalazine): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12584" href="/d/html/12584.html" rel="external">see "Mesalamine (mesalazine): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F193412"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Apriso;</li>
<li>Asacol HD [DSC];</li>
<li>Canasa;</li>
<li>Delzicol;</li>
<li>Lialda;</li>
<li>Pentasa;</li>
<li>Rowasa;</li>
<li>SfRowasa</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867474"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Asacol 800 [DSC];</li>
<li>Asacol [DSC];</li>
<li>Mezavant;</li>
<li>Mezera;</li>
<li>Octasa;</li>
<li>Pentasa;</li>
<li>Salofalk;</li>
<li>TEVA-5 ASA</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F193456"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        5-Aminosalicylic Acid Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F193417"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Choose the formulation that delivers mesalamine to the anatomic location of disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508'])">Ref</a></span>). Oral tablets and capsules generally deliver mesalamine near the terminal ileum of the small intestine and throughout the large intestine, except Pentasa, which delivers therapeutic quantities throughout both the small and large intestines. Rectal suppositories deliver mesalamine to the rectum, rectal foams [Canadian product] reach the sigmoid colon, and rectal suspensions reach the splenic flexure.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="44cab968-73a8-49fd-80c1-1d7c36630545">Crohn disease, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease, mild to moderate (alternative agent) (Canadian labeled use; US off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The Canadian Association of Gastroenterology recommends against routine use of mesalamine for Crohn disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31294378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31294378'])">Ref</a></span>). In patients with limited ileocolonic involvement who prefer to avoid glucocorticoids, some experts may use an oral mesalamine formulation that delivers mesalamine throughout the small and large intestine (eg, Pentasa) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Regueiro.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Regueiro.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Pentasa: <b>Oral:</b> 1 g 3 to 4 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a3263f8-b690-4df1-9666-48a664cf6bc9">Ulcerative colitis, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, mild to moderate: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Generic products may be available.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Induction of remission: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Choice of specific treatment is dependent on distribution of disease. <b>
<i>Ulcerative proctitis: </i></b>Treatment generally involves suppositories alone; however, in patients who prefer to avoid topical therapy or do not achieve response with topical therapy, consider oral mesalamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576644'])">Ref</a></span>). <b>
<i>Ulcerative proctosigmoiditis</i>:</b> Treatment generally involves rectal foam or suspension alone; however, in patients who prefer to avoid topical therapy or do not achieve response with topical therapy, consider oral mesalamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576644'])">Ref</a></span>). <b>
<i>Left-sided or extensive colitis</i>
<i>: </i></b>Treatment generally involves both oral and topical mesalamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576644','lexi-content-ref-AlHashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576644','lexi-content-ref-AlHashash.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Initial dosing regimens include: </b>
<b></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Topical treatments:</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Suppositories: Note: </b>Instruct patient to retain for 1 to 3 hours or longer if possible.</p>
<p style="text-indent:-2em;margin-left:12em;">Canasa suppository: <b>Rectal:</b> 1 g once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:12em;">Mezera suppository [Canadian product]: <b>Rectal:</b> 1 g once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:12em;">Pentasa suppository (Canadian labeling; not in US labeling): <b>Rectal:</b> 1 g once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:12em;">Salofalk suppository [Canadian product]: <b>Rectal:</b> 500 mg 2 or 3 times daily or 1 g once daily at bedtime. <b></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Rectal foam:</b>
<b>Note:</b> Instruct patient to retain for up to 8 hours if possible.</p>
<p style="text-indent:-2em;margin-left:12em;">Mezera rectal foam [Canadian product]: <b>Rectal:</b> 2 g (2 actuations) once daily at bedtime. <b></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Rectal suspension:</b>
<b>Note:</b> Instruct patient to retain for up to 8 hours if possible.</p>
<p style="text-indent:-2em;margin-left:12em;">Pentasa rectal suspension (Canadian labeling; not in US labeling): <b>Rectal:</b> 1 g or 4 g enema once daily at bedtime; choose dose based on disease severity.</p>
<p style="text-indent:-2em;margin-left:12em;">Rowasa rectal suspension: <b>Rectal:</b> 4 g enema once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:12em;">Salofalk rectal suspension [Canadian product]: <b>Rectal:</b> 4 g enema once daily at bedtime. <b></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral treatments: Note: </b>Oral tablets and capsules may be dosed once daily instead of multiple times daily; there is no significant difference in efficacy and safety (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605','lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605','lexi-content-ref-30576644'])">Ref</a></span>). For induction of remission, doses ≥2 g/day are more effective than lower doses and are generally recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Apriso (off-label use): <b>Oral:</b> 1.5 to 4.5 g once each morning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Asacol HD: <b>Oral:</b> 1.6 g 3 times daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Delzicol: <b>Oral:</b> 800 mg 3 times daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Lialda: <b>Oral:</b> 2.4 to 4.8 g once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Mesalamine 400 mg tablet [Canadian product]: <b>Oral:</b> 2.4 to 4.8 g/day in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576644','lexi-content-ref-AlHashash.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576644','lexi-content-ref-AlHashash.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Mezavant [Canadian product]: <b>Oral:</b> 2.4 to 4.8 g once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Mezera [Canadian product]: <b>Oral:</b> 1 g 3 times daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Octasa [Canadian product]: <b>Oral:</b> 3.2 to 4.8 g daily in 1 or more divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">Pentasa: <b>Oral:</b> 1 g 4 times daily.</p>
<p style="text-indent:-2em;margin-left:10em;">Salofalk tablet [Canadian product]: <b>Oral: </b>1 g 3 or 4 times daily. <b>
<i></i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration of induction therapy: </b>Usual course is 4 to 8 weeks before transitioning to maintenance treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance of remission: Note: </b>In most cases, it is appropriate to continue the medication(s) used for induction of remission. For ulcerative proctitis, maintenance therapy is generally only indicated for patients with &gt;1 flare per year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Topical treatments:</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Suppositories: Note: </b>Instruct patient to retain for 1 to 3 hours or longer if possible. <b></b></p>
<p style="text-indent:-2em;margin-left:10em;">Canasa suppository (off-label use): <b>Rectal:</b> 1 g once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605','lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605','lexi-content-ref-30576644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Mezera suppository [Canadian product] (off-label use): <b>Rectal:</b> 1 g once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605','lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605','lexi-content-ref-30576644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Pentasa suppository (Canadian labeling; not in US labeling): <b>Rectal:</b> 1 g once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:10em;">Salofalk suppository [Canadian product] (off-label use): <b>Rectal:</b> 500 mg 2 times daily or 1 g once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605','lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605','lexi-content-ref-30576644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Rectal suspension:</b>
<b>Note:</b> Instruct patient to retain for up to 8 hours if possible. <b></b></p>
<p style="text-indent:-2em;margin-left:10em;">Pentasa rectal suspension (Canadian labeling; not in US labeling): <b>Rectal:</b> 1 g or 4 g enema once daily at bedtime; choose dose based on disease severity.</p>
<p style="text-indent:-2em;margin-left:10em;">Rowasa rectal suspension (off-label use): <b>Rectal:</b> 4 g enema once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576644','lexi-content-ref-AlHashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576644','lexi-content-ref-AlHashash.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Salofalk rectal suspension [Canadian product]: <b>Rectal:</b> 2 g enema once daily at bedtime every day <b>or</b> 4 g enema once daily at bedtime every second or third day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral treatments:</b>
<b>Note: </b>Oral maintenance doses may be lower than those used for induction of remission; however, some patients require maintenance doses &gt;3 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576644','lexi-content-ref-AlHashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576644','lexi-content-ref-AlHashash.1'])">Ref</a></span>). Oral tablets and capsules may be dosed once daily instead of multiple times daily; there is no significant difference in efficacy and safety (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605','lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605','lexi-content-ref-30576644'])">Ref</a></span>). <b></b></p>
<p style="text-indent:-2em;margin-left:8em;">Apriso: <b>Oral:</b> 1.5 to 3 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Delzicol: <b>Oral:</b> 1.6 to 2.4 g/day in 1 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Lialda: <b>Oral:</b> 2.4 to 3.6 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Mesalamine 400 mg tablet [Canadian product]: <b>Oral:</b> 1.6 to 2.4 g/day in 1 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28368909','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28368909','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Mezavant [Canadian product]: <b>Oral:</b> 2.4 to 3.6 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Pentasa (Canadian labeling; not in US labeling): <b>Oral:</b> 1.5 to 4 g/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1','lexi-content-ref-24474233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1','lexi-content-ref-24474233'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990702"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Use with caution along with appropriate monitoring of kidney function in patients with kidney impairment (ie, eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>) or on dialysis, as prompt identification and management of acute kidney injury is key (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140','lexi-content-ref-15188168','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140','lexi-content-ref-15188168','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Ensure adequate hydration to prevent stone formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Kidney impairment prior to treatment initiation:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: <b>Oral, rectal:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>:<b> Oral, rectal: </b>No dosage adjustment necessary. <b>Note:</b> Due to rare, but serious, adverse effects on the kidney (eg, interstitial nephritis, acute kidney injury) reported with mesalamine use, collaboration with an appropriate specialist (eg, nephrologist) along with more frequent monitoring may be warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable: Mesalamine (5-ASA) and <i>N</i>-acetyl-5-ASA: Dialyzable (% unknown) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10809829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10809829'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, rectal:</b> Data on the safety of mesalamine treatment in patients with end-stage kidney disease (ESKD) are lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140'])">Ref</a></span>). No dosage adjustment necessary but use with caution and with frequent monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Dialyzability unknown (has not been studied): <b>Oral, rectal:</b> Data on the safety of mesalamine treatment in patients with ESKD are lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140'])">Ref</a></span>). No dosage adjustment necessary but use with caution and utilize the lowest effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b>
<b>Oral, rectal:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Oral, rectal:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Nephrotoxicity during treatment:</i></b> Nephrotoxicity is most often due to acute or chronic interstitial nephritis, which may occur within the first 12 months or after several years. Interstitial nephritis is idiosyncratic and not dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140','lexi-content-ref-15188168']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140','lexi-content-ref-15188168'])">Ref</a></span>). Acute kidney injury due to mesalamine-induced nephrolithiasis has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chebion.1','lexi-content-ref-29277882','lexi-content-ref-24478817','lexi-content-ref-31261253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chebion.1','lexi-content-ref-29277882','lexi-content-ref-24478817','lexi-content-ref-31261253'])">Ref</a></span>). Permanently discontinue therapy in patients who experience mesalamine-induced nephrotoxicity. Additional measures (eg, corticosteroids, hydration) may be necessary depending on the underlying pathology of the kidney injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17243140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17243140'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988030"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; evaluate risk versus benefit in patients with preexisting impairment.</p></div>
<div class="block doe drugH1Div" id="F193418"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Use with caution.</p></div>
<div class="block dop drugH1Div" id="F24760495"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12584" href="/d/html/12584.html" rel="external">see "Mesalamine (mesalazine): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information</b>: Some oral products are not bioequivalent and should not be interchanged (ie, two Delzicol 400 mg capsules are not interchangeable or substitutable with one mesalamine 800 mg delayed-release tablet).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="00ded6ac-d79a-4f10-bd48-7b77558ae0de">Crohn disease; treatment; maintenance of remission</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease; treatment (mild to moderate disease); maintenance of remission:</b> Limited data available: Children and Adolescents: Oral: 50 to 100 mg/kg/day divided every 6 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15272257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15272257'])">Ref</a></span>); maximum dose: 1,000 mg/dose</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20a8b537-759c-482e-8049-bfb874012cfe">Ulcerative colitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis; treatment (mild to moderate disease): Note:</b> Oral aminosalicylate (5-ASA) therapy including mesalamine is recommended as first-line induction and maintenance therapy for mild to moderate ulcerative colitis; for induction, if no response after 2 to 3 weeks of oral therapy, treatment modification should be considered. Combination therapy of oral and rectal 5-ASA therapy is more effective than oral monotherapy and may be necessary in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<span style="text-decoration: underline">Oral:</span></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fixed dosing: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Delayed-release capsule (twice-daily dosing):</p>
<p style="text-indent:-2em;margin-left:10em;">Delzicol: Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:12em;">17 to &lt;33 kg: Oral: 800 mg in the morning and 400 mg in the evening for 6 weeks; maximum daily dose: 1,200 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:12em;">33 to &lt;54 kg: Oral: 1,200 mg in the morning and 800 mg in the evening for 6 weeks; maximum daily dose: 2,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:12em;">54 to 90 kg: Oral: 1,200 mg in the morning and 1,200 mg in the evening for 6 weeks; maximum daily dose: 2,400 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Delayed-release tablet (once-daily dosing):</p>
<p style="text-indent:-2em;margin-left:10em;">Lialda: Children and Adolescents weighing ≥24 kg:</p>
<p style="text-indent:-2em;margin-left:12em;">24 to 35 kg: Oral: 2,400 mg once daily for the first 8 weeks of therapy, then decrease dose to 1,200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;35 to 50 kg: Oral: 3,600 mg once daily for the first 8 weeks of therapy, then decrease to 2,400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;50 kg: Oral: 4,800 mg once daily for the first 8 weeks of therapy, then decrease to 2,400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Weight-directed dosing</i>: Limited data available: Children and Adolescents: Oral: 60 to 80 mg/kg/day in 2 divided doses or once daily; dosing interval dependent on dosage form; maximum daily dose: 4,800 mg<b>/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357'])">Ref</a></span>); in patients with milder ulcerative colitis, doses as low as 30 mg/kg/day may be effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357','lexi-content-ref-25419597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357','lexi-content-ref-25419597'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<span style="text-decoration: underline">Rectal:</span> Limited data available: Children and Adolescents: Rectal enema, foam: 25 mg/kg/dose once daily; maximum dose: 1,000 mg/dose. <b>Note:</b> Although higher doses of up to 4,000 mg have been used, they have not been shown to be more effective. The utility of mesalamine suppository is limited to proctitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51129317"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments may be necessary since mesalamine is renally eliminated; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51129318"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; evaluate risk versus benefit in patients with preexisting impairment.</p></div>
<div class="block arsc drugH1Div" id="F56412902"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Delayed hypersensitivity reactions have been associated with mesalamine, including drug <b>fever</b>; involvement of the heart (<b>myocarditis/pericarditis</b>), kidney (<b>interstitial nephritis</b>), liver (ranging from asymptomatic and mild <b>increased serum alanine aminotransferase</b> levels to cholestatic or hepatocellular<b> hepatic injury</b>), pancreas (<b>pancreatitis</b>), blood system (<b>neutropenia</b>, <b>thrombocytopenia</b>, <b>aplastic anemia</b>), and lung (<b>interstitial pulmonary disease</b>); and serum sickness-like reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32147005','lexi-content-ref-28123193','lexi-content-ref-33657605','lexi-content-ref-14555914','lexi-content-ref-23321335','lexi-content-ref-21960800','lexi-content-ref-30508908','lexi-content-ref-20926880','lexi-content-ref-30946233','lexi-content-ref-12235076','lexi-content-ref-29722441','lexi-content-ref-23467507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32147005','lexi-content-ref-28123193','lexi-content-ref-33657605','lexi-content-ref-14555914','lexi-content-ref-23321335','lexi-content-ref-21960800','lexi-content-ref-30508908','lexi-content-ref-20926880','lexi-content-ref-30946233','lexi-content-ref-12235076','lexi-content-ref-29722441','lexi-content-ref-23467507'])">Ref</a></span>). Isolated hypereosinophilia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10213581','lexi-content-ref-19309777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10213581','lexi-content-ref-19309777'])">Ref</a></span>), as well as peripheral <b>eosinophilia </b>and organ involvement, <b>drug reaction with eosinophilia and systemic symptoms</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9149065','lexi-content-ref-8298382','lexi-content-ref-29574433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9149065','lexi-content-ref-8298382','lexi-content-ref-29574433'])">Ref</a></span>), and <b>eosinophilic granulomatosis with polyangiitis</b> (Churg-Strauss syndrome) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16859609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16859609'])">Ref</a></span>) have been described. Severe cutaneous adverse reactions (SCARs) have also been reported, including <b>Stevens-Johnson syndrome</b>, <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30112729','lexi-content-ref-17309074','lexi-content-ref-29931986']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30112729','lexi-content-ref-17309074','lexi-content-ref-29931986'])">Ref</a></span>), <b>acute generalized exanthematous pustulosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28329471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28329471'])">Ref</a></span>), and bullous <b>fixed drug eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29446099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29446099'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Delayed hypersensitivity reactions: Non–dose-related, immunologic; SCARs are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>). Myocarditis/pericarditis: May be caused by direct toxic effect on the myocardium or pericardium, cell-mediated hypersensitivity reaction, or humoral antibody response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28123193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28123193'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed hypersensitivity reactions: Varied. SCARs usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>) but have been described within 3 days after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29574433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29574433'])">Ref</a></span>). Myocarditis/pericarditis: Usually within 28 days of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29722441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29722441'])">Ref</a></span>). Acute interstitial nephritis: Within 6 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32147005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32147005'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of hypersensitivity to aspirin; although, there is shared structural similarity, unlikely to lead to cross-reactions with mesalamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24634525']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24634525'])">Ref</a></span>), and several reports document tolerance of mesalamine in the setting of aspirin hypersensitivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20535023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20535023'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity was postulated in patients with history of sulfasalazine hypersensitivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20926880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20926880'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Intolerance syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Exacerbation of <b>diarrhea</b>, <b>fever</b>, and <b>abdominal pain</b> (<b>intolerance syndrome</b>) has been noted in 7% to 14% of patients with ulcerative colitis in the literature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32013315','lexi-content-ref-28063246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32013315','lexi-content-ref-28063246'])">Ref</a></span>). These symptoms are often misdiagnosed as exacerbation of ulcerative colitis, resulting in unnecessary treatment, including increased risk of colectomy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33159485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33159485'])">Ref</a></span>) and increased risk of hospitalization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32013315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32013315'])">Ref</a></span>). Symptoms resolve upon drug discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32525567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32525567'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; dysbiosis may contribute to the development of intolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32013315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32013315'])">Ref</a></span>). Alternatively, diarrhea may result due to inhibition of ileal and colonic Na+/K+ ATPase or alteration of arachidonic acid metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29722441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29722441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; symptoms usually develop within 7 to 17 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32525567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32525567'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age &lt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32525567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32525567'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32525567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32525567'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Ulcerative colitis; in particular, pancolitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32525567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32525567'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Renal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Kidney impairment, including minimal change disease, acute and chronic <b>interstitial nephritis</b>, and <b>renal failure syndrome</b>, has been associated with mesalamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32147005','lexi-content-ref-21219240','lexi-content-ref-29722441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32147005','lexi-content-ref-21219240','lexi-content-ref-29722441'])">Ref</a></span>). <b>Nephrolithiasis</b> has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31261253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31261253'])">Ref</a></span>).<b> Nephrotoxicity</b> has been estimated at one in 4,000 patients/year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15882242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15882242'])">Ref</a></span>). In patients with chronic renal damage, discontinuation of mesalamine results in resolution in approximately one-third of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26619893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26619893'])">Ref</a></span>). Baseline kidney function and periodic monitoring is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33563584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33563584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown, likely idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23782372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23782372'])">Ref</a></span>). Salicylates, including mesalamine, inhibit synthesis of intra-renal prostaglandins, which may lead to nephrotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33563584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33563584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; chronic interstitial nephritis occurs within 1 year after initiation of mesalamine but may be delayed up to 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32147005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32147005'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26619893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26619893'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Possible association with HLA-DRB1*03:01 (3-fold increased risk of nephrotoxicity after 5-aminosalicylate [5-ASA] administration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26619893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26619893'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F193383"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse effects vary depending upon dosage form; frequency similar in adult and pediatric patients unless otherwise noted. Incidence usually on lower end with enema and suppository dosage forms.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1% to 21%)<span class="lexi-table-link-container"> (<a aria-label="Abdominal Pain table link" class="lexi-table-link" data-table-id="lexi-content-abdominal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abdominal-pain')">table 1</a>)</span><span class="table-link" style="display:none;">Abdominal Pain</span>, constipation (≤11%), eructation (≤26%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abdominal Pain" frame="border" id="lexi-content-abdominal-pain" rules="all">
<caption>
<b>Mesalamine: Adverse Reaction: Abdominal Pain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mesalamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mesalamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.2 to 2.4 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.4 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">53</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">52</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4.8 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">727</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.4 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">732</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">451</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rectal suspension enema</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">815</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">128</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "abdominal pain/cramps/discomfort"</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (3% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (children and adolescents: 15%; adults: 1% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (≤1%), alopecia (&lt;3%), pruritus (≤1%), skin rash (≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum triglycerides (&lt;3%), weight loss (children and adolescents: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (1%), anorectal pain (rectal: 1%; includes discomfort and pain on insertion of enema tip), bloody diarrhea (children and adolescents: 2%), diarrhea (2% to 8%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 2</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, dyspepsia (≤4%), flatulence (≤6%), gastroenteritis (≥2%), gastrointestinal hemorrhage, hemorrhoids (≥1%), lower abdominal pain (&lt;3%), nausea (≤4%), pancreatitis (≤2%), rectal pain (rectal: 1% to 2%), sclerosing cholangitis (children and adolescents: 2%), tenesmus (≥2%), upper abdominal pain (1% to 5%), vomiting</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption>
<b>Mesalamine: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mesalamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mesalamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.5 g/daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">367</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">185</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">451</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4.8 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">727</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.4 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">732</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rectal suspension enema</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">815</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">128</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (&lt;3%), urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit (&lt;3%), decreased hemoglobin (&lt;3%), rectal hemorrhage (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (≥2%), influenza (1% to 5%) viral infection (children and adolescents: ≥2%; including adenovirus)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (≤9%), fatigue (&lt;3%), nervousness (≥2%), pain (&lt;3%), paresthesia (≥2%), vertigo (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;3%), arthropathy (≥2%), back pain (≤6%), lower extremity pain (rectal: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children &amp; adolescents: 5%; adults: ≤1%), dyspnea (&lt;3%), flu-like symptoms (4%), rhinitis (8%), sinusitis (children and adolescents: 7%), upper respiratory tract infection (children and adolescents: ≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤3%)<span class="lexi-table-link-container"> (<a aria-label="Fever table link" class="lexi-table-link" data-table-id="lexi-content-fever" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fever')">table 3</a>)</span><span class="table-link" style="display:none;">Fever</span>, intolerance syndrome (2% to 3%; 7% to 14% in literature) (Mizuno 2020; Shimizu 2017)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fever" frame="border" id="lexi-content-fever" rules="all">
<caption>
<b>Mesalamine: Adverse Reaction: Fever</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mesalamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mesalamine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.2 to 2.4 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.4 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">732</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">451</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">173</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4.8 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">727</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rectal suppositories</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ulcerative proctitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">177</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rectal suspension enema</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">815</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">128</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, facial edema, hypotension, palpitations, pericarditis (Brown 2016), tachycardia, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, ecchymoses, eczema, erythema nodosum, lichen planus, nail disease, prurigo, skin photosensitivity, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, amenorrhea, heavy menstrual bleeding, increased amylase, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased thirst, Kawasaki-like syndrome (Waanders 1992)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abnormal stools, anorexia, duodenal ulcer, dysphagia, esophageal ulcer, fecal incontinence, increased serum lipase, oral candidiasis, oral mucosa ulcer, rectal polyp, rectal tenesmus</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hypomenorrhea, mastalgia, uterine hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocythemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression, drowsiness, insomnia, malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, lower limb cramp, myalgia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngolaryngeal pain, pulmonary infiltrates</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Abnormal T waves on ECG, chest pain, eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (Sinico 2006), myocarditis (Brown 2016), pericardial effusion, peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Rocci 2017), erythema of skin, psoriasis, pyoderma gangrenosum, Stevens-Johnson syndrome (Núñez Ortiz 2018), toxic epidermal necrolysis (Fukunaga 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, gout, nephrogenic diabetes insipidus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, cholecystitis, dysgeusia, fecal discoloration, frequent bowel movements, gastritis, increased appetite, mucus stools, perforated peptic ulcer, pruritus ani, rectal discharge, stomach discomfort, stomatitis, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea, dysuria, epididymitis, male infertility, oligospermia (reversible), urinary urgency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, eosinophilia (Usta 2009), granulocytopenia, leukopenia, lymphadenopathy, neutropenia (Frattini 2013), pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatic cirrhosis, hepatic failure, hepatic injury (cholestatic or hepatocellular) (Sehgal 2018), hepatic necrosis, hepatitis, hepatotoxicity, increased serum bilirubin, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, fixed drug eruption (Salman 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Lim 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, chills, confusion, drug fever, emotional lability, Guillain-Barré syndrome, hyperesthesia, hypertonia, intracranial hypertension (Rosa 2003), migraine, painful defecation, peripheral neuropathy, transverse myelitis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, lupus-like syndrome (Kirkpatrick 1999; Pent 1992), neck pain, rheumatoid arthritis, systemic lupus erythematosus (Gunnarsson 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, eye pain, swelling of eye</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Ear disease, eustachian tube congestion</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Sehgal 2018), chronic renal failure, idiopathic nephrotic syndrome, increased blood urea nitrogen, increased serum creatinine (Sehgal 2018), interstitial nephritis (Adiga 2020), nephrolithiasis (Simske 2019), nephrotoxicity, renal disease (including minimal change nephropathy), renal failure syndrome (Sehgal 2018), renal insufficiency (Sehgal 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, eosinophilic pneumonitis, exacerbation of asthma, hypersensitivity pneumonitis, interstitial pneumonitis, interstitial pulmonary disease (including allergic alveolitis) (Huang 2018), pharyngitis, pleurisy, pneumonitis, pulmonary fibrosis (alveolitis)</p></div>
<div class="block coi drugH1Div" id="F193397"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to mesalamine, aminosalicylates, salicylates, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe renal impairment (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>); severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Additional contraindications per specific Canadian product labeling: Existing gastric or duodenal ulcer, urinary tract obstruction (Mezera, Octasa, Pentasa, Salofalk); use in children &lt;2 years of age (Mezera, Pentasa, Salofalk [rectal suspension only]); patients unable to swallow intact tablet (Asacol, Asacol 800, Mezera, Octasa, Salofalk); renal parenchymal disease (Pentasa).</p></div>
<div class="block war drugH1Div" id="F193380"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Use with caution in patients with pre-existing skin conditions (including atopic dermatitis and atopic eczema); severe photosensitivity reactions have been reported. Use skin protection (protective clothing and broad-spectrum sunscreen) and avoid prolonged exposure to sunlight and ultraviolet light.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Evaluate risk versus benefit of therapy in patients with hepatic impairment; hepatic failure has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment, a history of renal disease, or those on nephrotoxic medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults; uncontrolled studies and postmarketing reports suggest an increased incidence of blood dyscrasias (ie, agranulocytosis, neutropenia, pancytopenia) in patients &gt;65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Apriso: Contains phenylalanine, which can be harmful to patients with phenylketonuria (PKU). Before prescribing, consider the combined daily amount of phenylalanine from all sources.</p>
<p style="text-indent:-2em;margin-left:4em;">• Asacol HD: Intact, partially intact, and/or tablet shells have been reported in the stool. Contains iron (4.9 mg per 800 mg tablet); use caution in patients receiving iron supplementation or at risk of iron overload.</p>
<p style="text-indent:-2em;margin-left:4em;">• Canasa suppositories: Contain saturated vegetable fatty acid esters (contraindicated in patients with allergy to these components). May stain surfaces including clothing, other fabrics, flooring, painted surfaces, enamel, granite, marble, and vinyl. Avoid contact with these surfaces.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delzicol: Intact, partially intact, and/or tablet shells have been reported in the stool. Contains iron (2.7 mg/400 mg capsule); use caution in patients receiving iron supplementation or at risk of iron overload.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mezera foam [Canadian product]: Contains metabisulfite salts, which may cause severe hypersensitivity reactions (ie, anaphylaxis) in patients with sulfite allergies. Also contains propylene glycol, which may cause lactic acidosis, hyperosmolality, hemolysis, and CNS depression; slight to mild skin irritation due to propylene glycol may occur. Additionally, contains cetostearyl alcohol, which may cause local skin reactions (eg, contact dermatitis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Octasa [Canadian product]: The 800 mg tablet contains lactose; avoid use in patients who have hereditary galactose intolerance, congenital lactase deficiency, or glucose-galactose malabsorption; use with caution in patients with lactose intolerance. Intact, partially intact, and/or tablet shells have been reported in the stool.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rowasa enema: Contain metabisulfite salts that may cause severe hypersensitivity reactions (ie, anaphylaxis) in patients with sulfite allergies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rowasa, sfRowasa: May stain direct contact surfaces including clothing, other fabrics, flooring, painted surfaces, enamel, granite, marble and vinyl. Choose a suitable location for product administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tablets: Patients with pyloric stenosis or other organic or functional upper GI obstructive disorders may have prolonged gastric retention of tablets, delaying the release of mesalamine in the colon; avoid use in patients at risk of upper GI obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bioequivalence: The Asacol HD 800 mg tablet has not been shown to be bioequivalent to two Delzicol 400 mg capsules. Two Delzicol 400 mg capsules have not been shown to be interchangeable or substitutable with one mesalamine 800 mg delayed-release tablet.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urine discoloration: Urine may appear reddish-brown when it comes in contact with surfaces or water (eg, in toilet) treated with hypochlorite-containing bleach; if discoloration occurs, instruct patients to observe urine flow as it leaves the body and contact health care provider if discoloration is seen prior to contact with any surface or water.</p></div>
<div class="block foc drugH1Div" id="F193391"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Delzicol: 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pentasa: 250 mg [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pentasa: 500 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Apriso: 0.375 g [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.375 g</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Enema, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SfRowasa: 4 g/60 mL (60 mL) [sulfite free; contains edetate (edta) disodium, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 g (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rowasa: 4 g [contains edetate (edta) disodium, potassium metabisulfite, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 g</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suppository, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Canasa: 1000 mg (30 ea, 42 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 mg (1 ea, 6 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asacol HD: 800 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lialda: 1.2 g</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 800 mg, 1.2 g</p></div>
<div class="block geq drugH1Div" id="F193376"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F193399"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Apriso Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.375 g (per each): $5.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Mesalamine ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.375 g (per each): $1.50 - $4.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Extended Release</b> (Mesalamine ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $6.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Extended Release</b> (Pentasa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $3.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $7.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Delzicol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $4.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Mesalamine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $4.19 - $4.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Enema</b> (Mesalamine Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g (per mL): $0.38 - $0.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Enema</b> (SfRowasa Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g/60 mL (per mL): $1.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Mesalamine-Cleanser Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g (per each): $167.35 - $171.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Rowasa Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g (per each): $534.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suppository</b> (Canasa Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $46.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suppository</b> (Mesalamine Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $38.20 - $44.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Lialda Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.2 g (per each): $11.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Mesalamine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.2 g (per each): $10.11 - $10.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg (per each): $9.27</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867475"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Enema, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pentasa: 1 g (100 mL); 4 g (100 mL) [contains edetate (edta) sodium (tetrasodium), sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salofalk: 2 g (60 g); 4 g (60 g) [contains edetate (edta) disodium, potassium metabisulfite, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Foam, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mezera: 1 g/actuation (80 g) [contains cetostearyl alcohol, disodium edta, propylene glycol, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suppository, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mezera: 1000 mg (30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pentasa: 1000 mg (10 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salofalk: 500 mg (30 ea); 1000 mg (30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asacol: 400 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asacol 800: 800 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mezavant: 1.2 g</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mezera: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Octasa: 800 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Octasa: 1.6 g [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salofalk: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pentasa: 500 mg, 1000 mg</p></div>
<div class="block adm drugH1Div" id="F193394"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> For all formulations, maintain adequate hydration during therapy (to minimize nephrolithiasis risk).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:6em;">Apriso: Swallow capsule whole; do not break, chew, crush, or cut. Do not administer with antacids.</p>
<p style="text-indent:-2em;margin-left:6em;">Delzicol: Swallow capsule whole with water; do not break, chew, crush, or cut. If a patient is unable to swallow the capsule, may open capsule and swallow capsule contents whole (do not cut, chew, break, or crush the contents).</p>
<p style="text-indent:-2em;margin-left:6em;">Pentasa: Swallow capsule whole; do not crush or chew; if a patient is unable to swallow the capsule, may open capsule and sprinkle the entire contents (controlled-release beads) onto yogurt or applesauce.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Swallow whole; do not break, chew, cut, or crush.</p>
<p style="text-indent:-2em;margin-left:6em;">Asacol 800 [Canadian product]: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:6em;">Asacol [Canadian product]: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:6em;">Asacol HD: Administer on an empty stomach (at least 1 hour before or 2 hours after a meal).</p>
<p style="text-indent:-2em;margin-left:6em;">Lialda: Administer with a meal.</p>
<p style="text-indent:-2em;margin-left:6em;">Mezavant [Canadian product]: Administer with a meal.</p>
<p style="text-indent:-2em;margin-left:6em;">Mezera [Canadian product]: Administer before meals.</p>
<p style="text-indent:-2em;margin-left:6em;">Octasa [Canadian product]: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:6em;">Pentasa [Canadian product]: Administer with meals.</p>
<p style="text-indent:-2em;margin-left:6em;">Salofalk [Canadian product]: Administer before meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, delayed and extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Delayed-release and ER tablets should be swallowed whole. Do not cut, chew, or crush. Delayed-release rectal suppository and enema formulations are available but no IR tablet, capsule, or oral solution formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, close clinical monitoring is advised in the immediate postoperative phase for the theoretical circumstance of reduced absorption after bariatric surgery. Consider use or conversion to delayed-release formulation in high-risk scenarios.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal enema:</b> Shake bottle well. Instruct patient to lie on left side with left leg extended and right leg flexed forward for balance, or in “knee-chest” position. Insert lubricated applicator tip into the rectum and point slightly toward the navel. Grasp bottle firmly and tilt so nozzle is aimed toward the back; squeeze slowly to instill medication. After administration, withdraw and discard bottle. Retain enemas for 8 hours or as long as practical.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal foam (Mezera [Canadian product])</b>: Warm canister to room temperature (15°C to 30°C [59°F to 86°F]). Attach applicator to canister; shake for ~20 seconds. Insert applicator as far into the rectum as comfortable for patient. Press pump dome once and slowly release it to administer dose; hold applicator in rectum for 10 to 15 seconds after dose administered. For the second spray, press dome again and release slowly; wait a further 10 to 15 seconds, then remove the applicator and dispose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Suppository:</b> Remove foil wrapper; avoid excessive handling. Insert into rectum. Retain suppository for 1 to 3 hours or longer. Do not cut or break suppository.</p></div>
<div class="block admp drugH1Div" id="F52613263"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> For all formulations, maintain adequate hydration during therapy to minimize nephrolithiasis risk.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:6em;">Apriso: Do not administer with antacids. Swallow capsule whole with water; do not break, chew, crush, or cut.</p>
<p style="text-indent:-2em;margin-left:6em;">Delzicol: Swallow capsule whole with water; do not break, chew, crush, or cut. If a patient is unable to swallow the capsule, may open capsule and swallow capsule contents whole (do not cut, chew, break, or crush, or cut the contents). Ensure that all contents are swallowed and no contents are retained in the mouth.</p>
<p style="text-indent:-2em;margin-left:6em;">Pentasa: If a patient is unable to swallow the capsule, some clinicians support opening the capsules and placing the contents (controlled release beads) on yogurt or peanut butter (Crohn's &amp; Colitis Foundation of America). There are currently no published data evaluating the safety/efficacy of this practice. The contents of the capsules should not be chewed or crushed.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Asacol HD: Administer on an empty stomach, at least 1 hour before and 2 hours after a meal. Swallow tablets whole; do not break, chew, or crush; do not break outer coating.</p>
<p style="text-indent:-2em;margin-left:6em;">Lialda: Administer with a meal. Swallow tablets whole; do not break outer coating.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal:</p>
<p style="text-indent:-2em;margin-left:4em;">Enema: Rowasa: Shake well before use. Instruct patient to lie on left side with left leg extended and right leg flexed forward for balance, or in "knee-chest" position. Insert lubricated applicator tip into the rectum and point slightly toward the navel. Grasp bottle firmly and tilt so nozzle is aimed toward the back; squeeze slowly to instill medication. After administration, withdraw and discard bottle. Retain enema for 8 hours or as long as practical.</p>
<p style="text-indent:-2em;margin-left:4em;">Suppository: Canasa: Remove foil wrapper; avoid excessive handling. Insert into rectum. Retain suppository for at least 1 to 3 hours for maximum benefit.</p></div>
<div class="block use drugH1Div" id="F193393"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Apriso: Maintenance of remission of ulcerative colitis in adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Asacol HD: Treatment of moderately active ulcerative colitis in adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Delzicol: Treatment of mildly to moderately active ulcerative colitis in patients ≥5 years of age; maintenance of remission of ulcerative colitis in adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Lialda: Treatment of mildly to moderately active ulcerative colitis in patients weighing ≥24 kg; treatment and maintenance of remission of mildly to moderately active ulcerative colitis in adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Pentasa: Treatment and maintenance of remission of mildly to moderately active ulcerative colitis in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Treatment of active mild to moderate distal ulcerative colitis (suspension only), proctosigmoiditis (suspension only), or proctitis (suspension and suppository) in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Asacol, Mezavant: Treatment and maintenance of remission of mildly to moderately active ulcerative colitis.</p>
<p style="text-indent:-2em;margin-left:6em;">Asacol 800: Treatment of moderately active ulcerative colitis.</p>
<p style="text-indent:-2em;margin-left:6em;">Mezera: Treatment of active mild to moderate ulcerative colitis in adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Octasa: Treatment of moderately active ulcerative colitis.</p>
<p style="text-indent:-2em;margin-left:6em;">Pentasa: Treatment and maintenance of remission of mildly to moderately active ulcerative colitis; treatment and maintenance of remission of mild to moderate Crohn disease.</p>
<p style="text-indent:-2em;margin-left:6em;">Salofalk: Treatment of acute ulcerative colitis in adults; prevention of relapse of Crohn disease following bowel resection in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal foam: Mezera: Treatment of mildly active ulcerative colitis of the sigmoid colon and rectum.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal suppository and suspension: Treatment and maintenance of remission of distal ulcerative colitis (extending to splenic flexure) and as adjunctive therapy in more extensive disease (suspension only); treatment and maintenance of ulcerative proctitis (suppository only).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Based on the American Gastroenterological Association guidelines on the management of moderate to severe ulcerative colitis, if escalation therapy with biologic agents and/or immunomodulators or tofacitinib is required to achieve remission in patients who have failed 5-ASA therapy (eg, mesalamine), mesalamine should not be continued for induction and maintenance of remission (AGA [Feuerstein 2020]).</p></div>
<div class="block mst drugH1Div" id="F193463"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Mesalamine may be confused with mecamylamine, megestrol, memantine, metaxalone, methenamine</p>
<p style="text-indent:-2em;margin-left:4em;">Apriso may be confused with Apri</p>
<p style="text-indent:-2em;margin-left:4em;">Asacol may be confused with Ansaid, Os-Cal [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Lialda may be confused with Aldara</p>
<p style="text-indent:-2em;margin-left:4em;">Pentasa may be confused with Pancrease, Pangestyme</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299675"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F193385"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Avoid concurrent administration of antacids with the Apriso brand of mesalamine extended-release capsules. The optimal duration of dose separation is unknown. Other mesalamine products do not contain this interaction warning.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: 5-Aminosalicylic Acid Derivatives may decrease the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppressive Agents: 5-Aminosalicylic Acid Derivatives may enhance the myelosuppressive effect of Myelosuppressive Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopurine Analogs: 5-Aminosalicylic Acid Derivatives may enhance the myelosuppressive effect of Thiopurine Analogs. 5-Aminosalicylic Acid Derivatives may increase serum concentrations of the active metabolite(s) of Thiopurine Analogs. Specifically, exposure to the active 6-thioguanine nucleotides (6-TGN) may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Varicella Virus-Containing Vaccines: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.  Management: Avoid administration of salicylates for at least 6 weeks after adminstration of a varicella virus-containing vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): 5-Aminosalicylic Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists. 5-Aminosalicylic Acid Derivatives may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308169"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Oligospermia, which was improved following discontinuation of the drug, has been reported following use of mesalamine for inflammatory bowel disease (Shin 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Mesalamine does not impair fertility in females with inflammatory bowel disease (Mahadevan 2019).</p></div>
<div class="block pri drugH1Div" id="F5304690"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Mesalamine (5-ASA) and the metabolite N-acetyl-5-aminosalicylic acid (Ac-5-ASA) cross the placenta (Klotz 1993).</p>
<p style="text-indent:0em;margin-top:2em;">An increased rate of congenital malformations has not been observed in human studies.</p>
<p style="text-indent:0em;margin-top:2em;">Inflammatory bowel disease is associated with adverse pregnancy outcomes, including an increased risk of miscarriage, premature delivery, delivery of a low-birth-weight infant, and poor maternal weight gain. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes. When treatment for inflammatory bowel disease is needed in pregnant patients, mesalamine can be continued without interruption (Mahadevan 2019).</p></div>
<div class="block brc drugH1Div" id="F193400"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Mesalamine (5-ASA) and the metabolite N-acetyl-5-aminosalicylic acid (Ac-5-ASA) are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, lower concentrations of mesalamine (undetectable to 0.5 mg/L) and higher concentrations of the metabolite (0.2 to 9.3 mg/L) have been detected in human breast milk following oral and rectal doses ranging from 500 mg to 4.8 g/day. Based on these concentrations, the estimated exposure to the breastfeeding infant would be 0 to 0.075 mg/kg/day of mesalamine and 0.03 to 1.4 mg/kg/day of Ac-5-ASA. In a study of 10 women taking chronic oral doses of mesalamine 1.2 to 4.8 g/day, breast milk concentrations of mesalamine were highly variable (Datta 2018) but within ranges reported by the manufacturer. A second study of 13 breastfeeding women on chronic doses of oral or rectal mesalamine showed considerable variability between maternal dose and concentrations of the Ac-5-ASA metabolite in breast milk (Christensen 1994).</p>
<p style="text-indent:-2em;margin-left:2em;">Diarrhea in the breastfed infant has been observed in case reports (Ito 1993; Nelis 1989).</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment with mesalamine is considered compatible with breastfeeding, regardless of the preparation used. Mesalamine is one of the preferred 5-aminosalicylic acid derivatives for use in patients who are breastfeeding. Infants should be monitored for diarrhea (Mahadevan 2019). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F193401"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine or lactose.</p></div>
<div class="block mop drugH1Div" id="F193389"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function (prior to and periodically during therapy) and hydration; CBC (particularly in elderly patients); hepatic function; signs/symptoms of worsening acute intolerance syndrome, dermatologic toxicity, or hypersensitivity reactions.</p></div>
<div class="block pha drugH1Div" id="F193379"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline">Mesalamine (5-aminosalicylic acid) is the active component of sulfasalazine; the specific mechanism of action is unknown; however, it is thought that mesalamine modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF); action appears topical rather than systemic</p></div>
<div class="block phk drugH1Div" id="F193396"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rectal: Variable and dependent upon retention time, underlying GI disease, and colonic pH; Oral: Tablet: ~20% to 28%, Capsule: ~20% to 43%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Mesalamine (5-ASA): ~43%; N-acetyl-5-ASA: ~78%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic and via GI tract to N-acetyl-5-aminosalicylic acid.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 5-ASA and N-acetyl-5-ASA: Variable; ~ 25 hours (range: 2 to 296 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Apriso: ~4 hours; Delzicol: ~10 hours; Pentasa: ~3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Mezera [Canadian product]: ~1 hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Pentasa, Salofalk [Canadian products]: 2 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Asacol HD: ~24 hours (mean); Lialda: 9 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Canadian products: Asacol: 7 hours; Asacol 800: 10 hours; Mezavant: 8 hours (range: 4 to 34 hours); Mezera: ~4 hours; Octasa 800 mg: Median: 14 hours (fasting) to 30 hours (nonfasting); Octasa 1,600 mg: Delayed ~17.5 hours when nonfasting.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral, suppository: Urine (primarily as N-acetyl-5-ASA, ≤12% as unchanged drug); feces (unabsorbed mesalamine).</p>
<p style="text-indent:-2em;margin-left:4em;">Enema: Feces (primarily); urine (10% to 30%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F193402"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mesacol | Mezacol | Pentasa | Salcrozine | Salofalk | Vegaz od</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">5 asa | 5 Asa LP | 5 XR | Bufexan | Bufexan ap | Conductasa | Exotran | Mezavant | Numalazina | Pentasa | Rectocalm | Salofalk | Sekena | Suprimal | Yolecol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Claversal | Mezavant | Pentasa | Salofalk | Yaldigo</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mesalazine takeda | Mesasal | Mezavant | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Canasa | Cozycol | Mesacol | Mesagut | Mesala | Meslamin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Asamovon | Claversal | Colitofalk | Mesalaphar | Mesalazine ips | Mesalazine teva generics belgium | Mezavant | Pentasa</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Pentasa</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Mesalazin | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Asalit | Chron asa 5 | Mesacol | Mesacol Mmx | Mesalazina | Mesaneo | Pentasa</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mezavant | Pentasa | Salofalk | Yaldigo</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Pentasa</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mecolzine | Mesax | Pentasa | Salofalk | Salofalk Odd</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An jie sh | An jie sha | Etiasa | Hui di | Mei sha la qin huan shi | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Asacolon | Mecolzine | Melizina | Mesaflor | Mesax | Mesazina | Mesilax | Pentasa | Salofalk | Sulimax</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Pentasa | Salofalk | Salozinal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Asacolitin | Claversal | Mesalazin | Mesalazin allomedic | Mesalazin axicorp | Mesalazin Beragena | Mesalazin emramed | Mesalazin Eurim-Pharm | Mesalazin fd pharma | Mesalazin orifarm | Mesavancol | Mezavant | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Asacol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Pentasa | Salofalk | Suprimal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Pentasa | Salofalk | Salozinal | Yaldigo</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Marsalaz | Mesalamine | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Claversal | Mezavant | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Pentasa | Pentasa xtend</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mesalazin orion | Mesasal | Mezavant | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fivasa | Mesalazine Dci | Pentasa | Rowasa</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Asacol tlt | Coltec | Ipocol | Mesalazine kent | Mesalazine sandoz | Mesren | Mezavant xl | Octasa | Pentasa | Salofalk | Zintasa</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Asalazin | Cronezil | Empenox | Favorat | Laboxantryl | Mesagin | Mezavant | Salofalk</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Euro mesalazine | Mezavant xl | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Claversal | Huma col asa | Mezavant | Pentasa | Salcrozine | Salofalk | Xalazin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Salofalk</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Asacolon | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Pentasa | Rafassal</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">5a | Asacol | Bravasa | Coolgut | Cosacol | Inflacol | Mesacol | Mesagon | Mesahenz | Mesalacure | Mesalenz | Mesalo | Mesamax od | Mesavin sr | Meslo | Mezakool | Meztec | Mosart od | Pentasa | Procol od | Salofalk gr | Vegas | Walasa</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Awasalazin sr</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Asalex | Asamax | Asavixin | Claversal | Enterasin | Lextrasa | Mesaflor | Mesalazina | Mesalazina drm | Mesalazina eg | Mesalazina sandoz | Mesavancol | Pentacol | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mezacol | Pentasa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Lialda | Mesalazine aska | Mesalazine f | Mesalazine kemifa | Mesalazine kn | Mesalazine pfizer | Pentasa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Mesacol | Mesla | Pentasa xtend | Rowasa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Melazine | Mesacol | Mezavant xl | Mezine | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mezacol | Pentasa | Salcrozine | Salofalk</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Pentasa | Salofalk | Yaldigo</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Claversal | Colitofalk | Pentasa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Pentasa | Salofalk | Yaldigo</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Pentasa | Salcrozine faes</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Ateka | Mesalazina | Pentasa | Salofalk | Seramine | Valmesfar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mezavant xl | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Pentasa | Pentasa xtend</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Kiudro | Mesalazine bmodesto | Mesalazine fisher | Mesalazine PCH | Mezavant | Mezavant bmodesto | Pentasa | Salofalk | Yaldigo</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Claversal | Mesalazin orifarm | Mesalazin orion | Mesasal | Mezavant | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Asamax | Pentasa</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Mesacron | Numal | Pentasa | Resna | Salofalk</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Colzine | Masacol | Mesacam | Mesal | Mesazine | Meslo | Mezacol | Salzina</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Asamax | Colitan | Crohnax | Jucolon | Mesalazyna | Pentasa | Salaza | Salofalk | Salozinal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Apriso | Asacol | Canasa | Delzicol | Mesalamine | Mesalamine delayed release | Mesalamine extended release | Rowasa | Sf rowasa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Azzavix | Claversal | Messalazina | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">5 asa | Mesacol | Pentasa | Supsidine</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Asacol MR | Pentasa | Pentasa Xtend | Salcrozine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Mesalazina sofarfarm | Salofalk</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">5 asa | Asacol | Kansalazine | Mesacol | Mezavant | Pentasa | Salofalk | Samezil | Ulcolfry</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mezacol | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Claversal | Mesalazin orion | Mesasal | Mesavancol | Mezavant | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pentasa | Salofalk | Samezil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Pentasa | Salofalk | Salozinal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mesacol | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cinkasa | Fivasa | Mesatec | Pentasa | Rowasa</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Asazin | E.s. mesosel | Mesain | Osirec | Pentasa | Salmiden | Salofalk</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Colasa | Genalamine | Mezavant xl | Pentasa</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mesacol | Pentasa | Salofalk</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ibsol 1.2</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">5 asa | Mesacron | Mesalzin | Salofalk | Xalazina</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Barzfin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Asacol | Mezavant | Pentasa | Salofalk</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32147005">
<a name="32147005"></a>Adiga A, Goldfarb DS. The association of mesalamine with kidney disease. <i>Adv Chronic Kidney Dis</i>. 2020;27(1):72-76. doi:10.1053/j.ackd.2019.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/32147005/pubmed" id="32147005" target="_blank">32147005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AlHashash.1">
<a name="AlHashash.1"></a>Al Hashash J, Regueiro M. Medical management of low-risk adult patients with mild to moderate ulcerative colitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 13, 2021.</div>
</li>
<li>
<div class="reference">
                  Apriso (mesalamine) extended-release capsules [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; November 2022.</div>
</li>
<li>
<div class="reference">
                  Asacol (mesalamine) [product monograph]. Markham, Ontario, Canada: Allergan Inc; March 2021.</div>
</li>
<li>
<div class="reference">
                  Asacol 800 (mesalamine) delayed-release tablets [product monograph]. Markham, Ontario, Canada: Allergan Inc; March 2021.</div>
</li>
<li>
<div class="reference">
                  Asacol HD (mesalamine) delayed-release tablets [prescribing information]. Madison, NJ: Allergan USA Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of Severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9149065">
<a name="9149065"></a>Borum ML, Ginsberg A. Hypersensitivity to 5-ASA suppositories. <i>Dig Dis Sc</i>i. 1997;42(5):1076-1078. doi:10.1023/a:1018857607739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/9149065/pubmed" id="9149065" target="_blank">9149065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28123193">
<a name="28123193"></a>Brown G. 5-Aminosalicylic acid-associated myocarditis and pericarditis: A narrative review. <i>Can J Hosp Pharm</i>. 2016;69(6):466-472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/28123193/pubmed" id="28123193" target="_blank">28123193</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Canasa (mesalamine) rectal suppository [prescribing information]. Madison, NJ: Allergan USA Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chebion.1">
<a name="Chebion.1"></a>Chebion G, Bugni E, Gerin V, Daudon M, Castiglione V. Drug-induced nephrolithiasis and crystalluria: the particular case of the sulfasalazine derivatives. <i>Comptes Rendus. Chimie.</i> 2022;25(suppl 1):295-306. doi:10.5802/crchim.109</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8009971">
<a name="8009971"></a>Christensen LA, Rasmussen SN, Hansen SH. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. <i>Acta Obstet Gynecol Scand</i>. 1994;73(5):399-402. doi:10.3109/00016349409006251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/8009971/pubmed" id="8009971" target="_blank">8009971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23782372">
<a name="23782372"></a>Co ML, Gorospe EC. Pediatric case of mesalazine-induced interstitial nephritis with literature review. <i>Pediatr Int</i>. 2013;55(3):385-387. doi:10.1111/j.1442-200X.2012.03745.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/23782372/pubmed" id="23782372" target="_blank">23782372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29277882">
<a name="29277882"></a>Corbery B, Lebdai S, Borojeni S, Bigot P, Azzouzi AR, Culty T. Mesalazine: a novel etiology for drug-induced urinary calculi. <i>Urol J.</i> 2018;15(3):132-133. doi:0.22037/uj.v0i0.3902<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/29277882/pubmed" id="29277882" target="_blank">29277882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33657605">
<a name="33657605"></a>Correia JP, Ponte AI, Silva JC, Gomes AC, Afecto E. Mesalazine-induced acute pancreatitis: a rare adverse reaction but with important therapeutic implications in ulcerative colitis. <i>Eur J Gastroenterol Hepatol</i>. 2021;33(4):595. doi: 10.1097/MEG.0000000000001901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/33657605/pubmed" id="33657605" target="_blank">33657605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30431332">
<a name="30431332"></a>Datta P, Rewers-Felkins K, Kallem RR, Baker T, Hale TW. Determination of mesalamine levels in human milk as a function of dose. <i>Breastfeed Med</i>. 2019;14(2):98-101. doi:10.1089/bfm.2018.0111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/30431332/pubmed" id="30431332" target="_blank">30431332</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Delzicol (mesalamine) [prescribing information]. Madison, NJ: Allergan USA Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31945371">
<a name="31945371"></a>Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. <i>Gastroenterology.</i> 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/31945371/pubmed" id="31945371" target="_blank">31945371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15272257">
<a name="15272257"></a>Fish D, Kugathasan S. Inflammatory Bowel Disease. <i>Adolesc Med Clin</i>. 2004;15(1):67-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/15272257/pubmed" id="15272257" target="_blank">15272257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14555914">
<a name="14555914"></a>Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. <i>Inflamm Bowel Dis</i>. 2003;9(5):308-315. doi:10.1097/00054725-200309000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/14555914/pubmed" id="14555914" target="_blank">14555914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23321335">
<a name="23321335"></a>Frattini F, Crestani S, Vescovi PP, Franchini M. Pure white cell aplasia induced by mesalazine in a patient with ulcerative colitis. <i>Hematology</i>. 2013;18(3):181-182. doi:10.1179/1607845412Y.0000000043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/23321335/pubmed" id="23321335" target="_blank">23321335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30112729">
<a name="30112729"></a>Frey N, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. Stevens-johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: A population-based case-control study. <i>Drug Saf</i>. 2019;42(1):55-66. doi:10.1007/s40264-018-0711-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/30112729/pubmed" id="30112729" target="_blank">30112729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17309074">
<a name="17309074"></a>Fukunaga K, Ohda Y, Inoue T, Kono T, Miwa H, Matsumoto T. Toxic epidermal necrosis associated with mesalamine in a patient with ulcerative colitis. <i>Inflamm Bowel Dis</i>. 2007;13(8):1055-1056. doi:10.1002/ibd.20125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/17309074/pubmed" id="17309074" target="_blank">17309074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17243140">
<a name="17243140"></a>Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. <i>Inflamm Bowel Dis</i>. 2007;13(5):629-638. doi:10.1002/ibd.20099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/17243140/pubmed" id="17243140" target="_blank">17243140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33563584">
<a name="33563584"></a>Guillo L, D'Amico F, Achit H, et al. Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. <i>Dig Liver Dis</i>. 2021;53(6):691-696. doi:10.1016/j.dld.2021.01.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/33563584/pubmed" id="33563584" target="_blank">33563584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10483021">
<a name="10483021"></a>Gunnarsson I, Forslid J, Ringertz B. Mesalazine-induced lupus syndrome. <i>Lupus</i>. 1999;8(6):486-488. doi:10.1177/096120339900800616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/10483021/pubmed" id="10483021" target="_blank">10483021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21960800">
<a name="21960800"></a>Harris A, Eswaran S, Bosworth B, Gambarin-Gelwan M, Scherl EJ. Mesalamine-induced pneumonitis and serum sickness-like reaction. <i>Gastroenterol Hepatol (N Y)</i>. 2007;3(11):875-877<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/21960800/pubmed" id="21960800" target="_blank">21960800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26619893">
<a name="26619893"></a>Heap GA, So K, Weedon M, et al. Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease. <i>J Crohns Colitis</i>. 2016;10(2):149-158. doi:10.1093/ecco-jcc/jjv219. Erratum in: <i>J Crohns Colitis</i>. 2017;11(12):1509.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/26619893/pubmed" id="26619893" target="_blank">26619893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33159485">
<a name="33159485"></a>Hibiya S, Matsuyama Y, Fujii T, et al. 5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis. <i>Aliment Pharmacol Ther</i>. 2021;53(1):103-113. doi:10.1111/apt.16120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/33159485/pubmed" id="33159485" target="_blank">33159485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32525567">
<a name="32525567"></a>Hiraoka S, Fujiwara A, Toyokawa T, et al. Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. <i>J Gastroenterol Hepatol</i>. 2021;36(1):137-143. doi:10.1111/jgh.15138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/32525567/pubmed" id="32525567" target="_blank">32525567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30508908">
<a name="30508908"></a>Huang PH, Kuo CJ, Lin CW, et al. Mesalazine-related lung disease in a patient with ulcerative colitis: A case report. <i>Medicine</i> (Baltimore). 2018;97(48):e13242. doi:10.1097/MD.0000000000013242<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/30508908/pubmed" id="30508908" target="_blank">30508908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399. doi:10.1016/s0002-9378(11)90771-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24478817">
<a name="24478817"></a>Jacobsson H, Eriksen J, Karlén P. Mesalazine-induced renal calculi. <i>Am J Case Rep.</i> 2013;14:551-553. doi:10.12659/AJCR.889719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/24478817/pubmed" id="24478817" target="_blank">24478817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20926880">
<a name="20926880"></a>Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. <i>Dig Dis</i>. 2010;28(3):508-518. doi:10.1159/000320410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/20926880/pubmed" id="20926880" target="_blank">20926880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10203437">
<a name="10203437"></a>Kirkpatrick AW, Bookman AA, Habal F. Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease. <i>Can J Gastroenterol</i>. 1999;13(2):159-162. doi: 10.1155/1999/361431<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/10203437/pubmed" id="10203437" target="_blank">10203437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8102746">
<a name="8102746"></a>Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. <i>Lancet</i>. 1993;342(8871):618-619. doi:10.1016/0140-6736(93)91443-p<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/8102746/pubmed" id="8102746" target="_blank">8102746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30576644">
<a name="30576644"></a>Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. <i>Gastroenterology</i>. 2019;156(3):748-764. doi:10.1053/j.gastro.2018.12.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/30576644/pubmed" id="30576644" target="_blank">30576644</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lialda (mesalamine) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi:10.1038/ajg.2018.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8298382">
<a name="8298382"></a>Lim AG, Hine KR. Fever, vasculitic rash, arthritis, pericarditis, and pericardial effusion after mesalazine. <i>BMJ</i>. 1994;308(6921):113. doi:10.1136/bmj.308.6921.113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/8298382/pubmed" id="8298382" target="_blank">8298382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21219240">
<a name="21219240"></a>Linares V, Alonso V, Domingo JL. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. <i>Expert Opin Drug Saf</i>. 2011;10(2):253-263. doi:10.1517/14740338.2011.529898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/21219240/pubmed" id="21219240" target="_blank">21219240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Am J Obstet Gynecol</i>. 2019;220(4):308-323. doi:10.1016/j.ajog.2019.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7615189">
<a name="7615189"></a>McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. <i>Gastroenterology</i>. 1995;109(2):404-413.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/7615189/pubmed" id="7615189" target="_blank">7615189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30946233">
<a name="30946233"></a>Meczker Á, Mikó A, Gede N, et al; Hungarian Pancreatic Study Group. Retrospective matched-cohort analysis of acute pancreatitis induced by 5-aminosalicylic acid-derived drugs. <i>Pancreas</i>. 2019;48(4):488-495. doi:10.1097/MPA.0000000000001297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/30946233/pubmed" id="30946233" target="_blank">30946233</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mezavant (mesalamine) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mezera.1">
<a name="Mezera.1"></a>Mezera foam/suppository (mesalamine) [product monograph]. Blainville, Quebec, Canada: AVIR Pharma Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mezera.2">
<a name="Mezera.2"></a>Mezera tablet (mesalamine) [product monograph]. Blainville, Quebec, Canada: AVIR Pharma Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32013315">
<a name="32013315"></a>Mizuno S, Ono K, Mikami Y, et al. 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis. <i>Intest Res</i>. 2020;18(1):69-78. doi:10.5217/ir.2019.00084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/32013315/pubmed" id="32013315" target="_blank">32013315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10213581">
<a name="10213581"></a>Morice AH, Kumwenda J, Qureshi N, Curran A. Mesalazine activation of eosinophil. <i>Lancet</i>. 1997;350(9084):1105. doi:10.1016/s0140-6736(05)70471-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/10213581/pubmed" id="10213581" target="_blank">10213581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15882242">
<a name="15882242"></a>Muller AF, Stevens PE, McIntyre AS, Ellison H, Logan RF. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. <i>Aliment Pharmacol Ther</i>. 2005;21(10):1217-1224. doi:10.1111/j.1365-2036.2005.02462.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/15882242/pubmed" id="15882242" target="_blank">15882242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20535023">
<a name="20535023"></a>Murphy SJ, Mayer L, Abreu MT. Mesalamine (5-aminosalicylic acid) therapy well tolerated in a patient with aspirin hypersensitivity and ulcerative colitis. <i>J Clin Gastroenterol</i>. 2011;45(1):83-84. doi:10.1097/MCG.0b013e3181dffcb4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/20535023/pubmed" id="20535023" target="_blank">20535023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2563532">
<a name="2563532"></a>Nelis GF. Diarrhoea Due to 5-Aminosalicylic Acid in Breast Milk.<i> Lancet</i>. 1989;1(8634):383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/2563532/pubmed" id="2563532" target="_blank">2563532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>NICE Clinical Guideline 183. Diagnosis and management of drug allergy in adults, children and young people. <i>Drug Allergy</i>. Published September 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24474233">
<a name="24474233"></a>Nishikawa AM, Paladini L, Delfini R, Kotze PG, Clark O. Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with Pentasa mesalazine 2 g sachet. <i>Arq Gastroenterol</i>. 2013;50(4):297-303. doi:10.1590/S0004-28032013000400011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/24474233/pubmed" id="24474233" target="_blank">24474233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29931986">
<a name="29931986"></a>Núñez Ortiz A, Trigo Salado C, de la Cruz Ramírez MD, Herrera Justiniano JM, Leo Carnerero E. Topical mesalazine as a cause of Stevens-Johnson syndrome. <i>Rev Esp Enferm Dig</i>. 2018;110(11):736-738. doi:10.17235/reed.2018.5429/2017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/29931986/pubmed" id="29931986" target="_blank">29931986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octasa.1">
<a name="Octasa.1"></a>Octasa (mesalamine) 800 mg tablet [product monograph]. Rheinfelden, Switzerland: Tillotts Pharma AG; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octasa.2">
<a name="Octasa.2"></a>Octasa (mesalamine) 1600 mg tablet [product monograph]. Rheinfelden, Switzerland: Tillotts Pharma AG; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31294378">
<a name="31294378"></a>Panaccione R, Steinhart AH, Bressler B, et al. Canadian Association of Gastroenterology clinical practice guideline for the management of luminal Crohn's disease. <i>J Can Assoc Gastroenterol</i>. 2019;2(3):e1-e34. doi:10.1093/jcag/gwz019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/31294378/pubmed" id="31294378" target="_blank">31294378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1515833">
<a name="1515833"></a>Pent MT, Ganapathy S, Holdsworth CD, Channer KC. Mesalazine induced lupus-like syndrome. <i>BMJ</i>. 1992;305(6846):159. doi:10.1136/bmj.305.6846.159-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/1515833/pubmed" id="1515833" target="_blank">1515833</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pentasa (mesalamine) extended-release capsules [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; September 2023.</div>
</li>
<li>
<div class="reference">
                  Pentasa (mesalamine) [product monograph]. North York, Ontario, Canada: Ferring Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24634525">
<a name="24634525"></a>Poh J, Knowles S. Safety of 5-aminosalicylic acid derivatives in patients with sensitivity to acetylsalicylic acid and nonsteroidal anti-inflammatory drugs. <i>Can J Hosp Pharm</i>. 2014;67(1):35-38. doi:10.4212/cjhp.v67i1.1318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/24634525/pubmed" id="24634525" target="_blank">24634525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12235076">
<a name="12235076"></a>Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. <i>Gut</i>. 2002;51(4):536-539. doi:10.1136/gut.51.4.536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/12235076/pubmed" id="12235076" target="_blank">12235076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Regueiro.1">
<a name="Regueiro.1"></a>Regueiro M, Al Hashash J. Overview of the medical management of mild (low risk) Crohn disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20551460">
<a name="20551460"></a>Reinisch W, Angelberger S, Petritsch W; International AZT-2 Study Group, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. <i>Gut</i>. 2010;59(6):752-759. doi:10.1136/gut.2009.194159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/20551460/pubmed" id="20551460" target="_blank">20551460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28329471">
<a name="28329471"></a>Rocci E, Park K, Hutchens K, Winterfield L. First report of mesalamine (5-aminosalicylic acid) as the causative agent in a case of acute generalized exanthamous pustulosis. <i>Dermatol Online J</i>. 2017;23(1):13030/qt7046n97m<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/28329471/pubmed" id="28329471" target="_blank">28329471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12834704">
<a name="12834704"></a>Rosa N, Giamundo A, Jura A, Iaccarino G, Romano A. Mesalazine-associated benign intracranial hypertension in a patient with ulcerative colitis. <i>Am J Ophthalmol</i>. 2003;136(1):212-213. doi:10.1016/s0002-9394(02)02275-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/12834704/pubmed" id="12834704" target="_blank">12834704</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Rowasa (mesalamine) suspension [prescribing information]. Somerset, NJ: Meda Pharmaceuticals; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840605">
<a name="30840605"></a>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. <i>Am J Gastroenterol</i>. 2019;114(3):384-413. doi:10.14309/ajg.0000000000000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/30840605/pubmed" id="30840605" target="_blank">30840605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-sfRowasa.1">
<a name="sfRowasa.1"></a>sfRowasa (mesalamine) rectal suspension [prescribing information]. Somerset, NJ: Meda Pharmaceuticals; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29446099">
<a name="29446099"></a>Salman A, Seckin Gencosmanoglu D, Alahdab YO, Giménez-Arnau AM. Mesalazine-induced bullous fixed drug eruption. <i>Contact Dermatitis</i>. 2018;79(1):34-35. doi:10.1111/cod.12972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/29446099/pubmed" id="29446099" target="_blank">29446099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Salofalk.2">
<a name="Salofalk.2"></a>Salofalk rectal suspension (mesalamine) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; November 2022.</div>
</li>
<li>
<div class="reference">
                  Salofalk suppositories (mesalamine) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; November 2022.</div>
</li>
<li>
<div class="reference">
                  Salofalk tablets (mesalamine) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29722441">
<a name="29722441"></a>Sehgal P, Colombel JF, Aboubakr A, Narula N. Systematic review: safety of mesalazine in ulcerative colitis. <i>Aliment Pharmacol Ther</i>. 2018;47(12):1597-1609. doi:10.1111/apt.14688<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/29722441/pubmed" id="29722441" target="_blank">29722441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29574433">
<a name="29574433"></a>Shabtaie SA, Tan NY, Parikh RS, Papadakis KA. Concurrent Sweet's syndrome and myopericarditis following mesalamine therapy.<i> BMJ Case Rep</i>. 2018;2018:bcr2017223851. doi:10.1136/bcr-2017-223851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/29574433/pubmed" id="29574433" target="_blank">29574433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28063246">
<a name="28063246"></a>Shimizu H, Arai K, Tang J, Hosoi K, Funayama R. 5-Aminosalicylate intolerance causing exacerbation in pediatric ulcerative colitis. <i>Pediatr Int</i>. 2017;59(5):583-587. doi:10.1111/ped.13235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/28063246/pubmed" id="28063246" target="_blank">28063246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25144125">
<a name="25144125"></a>Shin T, Kobori Y, Suzuki K, et al. Inflammatory bowel disease in subfertile men and the effect of mesalazine on fertility. <i>Syst Biol Reprod Med</i>. 2014;60(6):373-376. doi:10.3109/19396368.2014.952391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/25144125/pubmed" id="25144125" target="_blank">25144125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31261253">
<a name="31261253"></a>Simsek M, de Boer NKH. Mesalazine and nephrolithiasis: leave no stone unturned. <i>Am J Gastroenterol</i>. 2019;114(8):1359-1360. doi:10.14309/ajg.0000000000000311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/31261253/pubmed" id="31261253" target="_blank">31261253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16859609">
<a name="16859609"></a>Sinico RA, Sabadini E, Maresca AM. Mesalazine-induced Churg-Strauss syndrome in a patient with Crohn's disease and sclerosing cholangitis. <i>Clin Exp Rheumatol</i>. 2006;24(2 Suppl 41):S104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/16859609/pubmed" id="16859609" target="_blank">16859609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23467507">
<a name="23467507"></a>Slim R, Amara J, Nasnas R, et al. Isolated fever induced by mesalamine treatment. <i>World J Gastroenterol</i>. 2013;19(7):1147-1149. doi:10.3748/wjg.v19.i7.1147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/23467507/pubmed" id="23467507" target="_blank">23467507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28368909">
<a name="28368909"></a>Suzuki Y, Iida M, Ito H, et al. 2.4 g Mesalamine (Asacol 400 mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. <i>Inflamm Bowel Dis</i>. 2017;23(5):822-832. doi:10.1097/MIB.0000000000001065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/28368909/pubmed" id="28368909" target="_blank">28368909</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Teva-5 ASA (5-aminosalicylic acid) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30044357">
<a name="30044357"></a>Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;67(2):257-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/30044357/pubmed" id="30044357" target="_blank">30044357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19309777">
<a name="19309777"></a>Usta Y, Ozen H, Gurakan F, et al. Hypereosinophilia due to mesalazine treatment. <i>J Clin Gastroenterol</i>. 2009;43(4):382. doi:10.1097/mcg.0b013e31816533a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/19309777/pubmed" id="19309777" target="_blank">19309777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15188168">
<a name="15188168"></a>Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. <i>Gastroenterology</i>. 2004;126(7):1733-1739. doi:10.1053/j.gastro.2004.03.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/15188168/pubmed" id="15188168" target="_blank">15188168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10809829">
<a name="10809829"></a>Verzijl JM, Kamphuis TJ, Rensma PL, van Roon EN. Clearance of an oral delayed-release mesalazine preparation (Salofalk((R))) by haemodialysis-pharmacokinetic profile of mesalazine related to the effects of dialysis. <i>Nephrol Dial Transplant.</i> 2000;15(5):736A-738A.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/10809829/pubmed" id="10809829" target="_blank">10809829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1992637">
<a name="1992637"></a>Waanders H, Thompson J. Kawasaki-like syndrome after treatment with mesalazine. <i>Am J Gastroenterol</i>. 1991;86(2):219-221.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/1992637/pubmed" id="1992637" target="_blank">1992637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25419597">
<a name="25419597"></a>Winter HS, Krzeski P, Heyman MB, et al. High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis. <i>J Pediatr Gastroenterol Nutr</i>. 2014;59(6):767-772. doi:10.1097/MPG.0000000000000530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/25419597/pubmed" id="25419597" target="_blank">25419597</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9614 Version 537.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
